Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Clinical Evidence, Evolving Indications, and Research-Frontier Mapping
Journal of Gastrointestinal Cancer · 28.10.2026 · 57 (1)
DOI: 10.1007/s12029-026-01596-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastrointestinal Cancer, online erschienen am 28.10.2026. Verfasst von Junpeng Luo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medical Center, Huaihe Hospital, Henan University, Kaifeng, Henan, China. hiccp@henu.edu.cn. Hauptthemen laut MEDLINE: Liver Neoplasms, Yttrium Radioisotopes, Carcinoma, Hepatocellular, Radioembolization, Therapeutic. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Key Scientific Research Project of Higher Education Institutions, Henan Provincial Medical Science and Technology Public Relations Program, Provincial Ministerial Co-Construction Key Project, Henan Provincial Medical Science and Technology Research Project.
Abstract (Originalsprache)
Yttrium-90 (Y-90) radioembolization, also termed selective internal radiation therapy (SIRT) or transarterial radioembolization (TARE), is used across the hepatocellular carcinoma (HCC) treatment spectrum as locoregional therapy, bridging or downstaging treatment, radiation segmentectomy, and an emerging partner for systemic therapy. SARAH and SIRveNIB did not show overall survival superiority over sorafenib; DOSISPHERE-01 supported personalized dosimetry; and LEGACY/RASER strengthened radiation segmentectomy in selected solitary HCC. Recent 2025–2026 studies have updated comparative TARE/TACE evidence and combination strategies. We synthesize clinical evidence by indication and integrate a bibliometric analysis of 1,472 high-specificity WoSCC-SCIE records through June 2026 as a triangulation tool, comparing research-frontier signals with unresolved clinical evidence gaps. These signals do not establish efficacy, but they help prioritize trials of Y-90 plus immunotherapy, standardized personalized dosimetry, and contemporary comparisons against TACE or current systemic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Medical Center, Huaihe Hospital, Henan University, Kaifeng, Henan, China. hiccp@henu.edu.cn.
- Department of Radiology, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
- Department of Otolaryngology, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
- Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Dongfeng East Road 651, Guangzhou, Guangdong Province, 510260, China.
- Department of Pathology, Henan Cancer Hospital, Zhengzhou, Henan, China.
ORCID-Profile: Junpeng Luo
Förderung
- Key Scientific Research Project of Higher Education Institutions
- Henan Provincial Medical Science and Technology Public Relations Program, Provincial Ministerial Co-Construction Key Project
- Henan Provincial Medical Science and Technology Research Project
Zitieren
APA
Luo, J., Qi, X., Wang, Y., Huang, Z., & Chen, T. (2026). Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Clinical Evidence, Evolving Indications, and Research-Frontier Mapping. Journal of Gastrointestinal Cancer, 57(1). https://doi.org/10.1007/s12029-026-01596-7
Vancouver
Luo J, Qi X, Wang Y, Huang Z, Chen T. Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Clinical Evidence, Evolving Indications, and Research-Frontier Mapping. Journal of Gastrointestinal Cancer. 2026;57(1). doi:10.1007/s12029-026-01596-7
BibTeX
@article{Luo2026,
author = {Luo, Junpeng and Qi, Xiao and Wang, Yandan and Huang, Zhimei and Chen, Tiandong},
title = {Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Clinical Evidence, Evolving Indications, and Research-Frontier Mapping},
journal = {Journal of Gastrointestinal Cancer},
year = {2026},
volume = {57},
number = {1},
doi = {10.1007/s12029-026-01596-7}
}
EUVIMED